 CAMBRIDGE, Mass.--BUSINESS WIRE--- VBIV--VBI Vaccines Inc. Nasdaq: VBIV VBI, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b2a study of VBI-2601 BRII-179, a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus HBV infection, in development in collaboration with Brii Biosciences. These early 